Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (262)	5/29/2008 5:25:58 PM
From: The Dodgy Ticker	Respond to of 368

Sangamo Biosciences (SGMO - Cramer's Take - Stockpickr) gave up $1.29, or 10.5%, to $11.04, after Brean Murray Carret & Co. analyst Jonathan Aschoff initiated coverage on the stock with a sell rating and a $5 price target. Aschoff expects trials on SB-509 -- which uses the company's zinc finger DNA-binding protein technology to modify genes -- in diabetic neuropathy will leave investors disappointed. I would love SGMO to drop to $5! I would back up the truck were that to happen.